| Bioactivity | Ompenaclid (RGX-202) is an oral small-molecule SLC6A8 transporter inhibitor. Ompenaclid robustly inhibits creatine import in vitro and in vivo, reduces intracellular phosphocreatine and ATP levels, and induces tumor apoptosis. Ompenaclid can be used for the research of cancer and duchenne muscular dystrophy[1][2]. | ||||||||||||
| Invitro | Ompenaclid (RGX-202; 10 μM; 96 hours) reduces cell growth, and reveals a nearly complete depletion of phosphocreatine (>99%), greater than 79% reduction in cellular creatine and a substantial (46%) reduction in intracellular ATP levels relative to control cells in hypoxia[1]. | ||||||||||||
| Name | Ompenaclid | ||||||||||||
| CAS | 353-09-3 | ||||||||||||
| Formula | C4H9N3O2 | ||||||||||||
| Molar Mass | 131.14 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Ompenaclid
CAS: 353-09-3 F: C4H9N3O2 W: 131.14
Ompenaclid (RGX-202) is an oral small-molecule SLC6A8 transporter inhibitor. Ompenaclid robustly inhibits creatine impor
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.